Dr. Goldstein is Associate Professor of Psychiatry, Radiology, Neurology, Pathology & Laboratory Medicine, Biomedical Engineering, and Electrical & Computer Engineering at Boston University School of Medicine, College of Engineering, and Photonics Center. He leads multidisciplinary research teams as Director of the Molecular Aging & Development Laboratory, Center for Biometallomics, and Neurotrauma Laboratory at Boston University School of Medicine. He co-directs the Biomarker Core, NIH-funded Boston University Alzheimer’s Disease Center, and the newly established Center for Translational Neuroimaging. While at Harvard Medical School, Dr. Goldstein discovered Alzheimer’s disease β-amyloid (Aβ) pathology in the lens of the eye (Goldstein et al., Lancet, 2003), the first evidence of Alzheimer’s pathology outside the brain. He predicted and subsequently identified Aβ lens pathology as the origin of cataracts in Down syndrome (Trisomy 21), a chromosomal disorder in which early-onset β-amyloid brain pathology is an invariant feature.

In 2001, Dr. Goldstein co-founded Neuroptix (now Cognoptix) with the goal of developing a drug-device combination eye scanner for early detection and monitoring of Alzheimer’s disease. He served the company for over a decade and recently rejoined Cognoptix to help move the Sapphire II system to the forefront of AD diagnostic technologies. He received his baccalaureate from Columbia, MD-PhD degrees from Yale, and clinical and research fellowships at Massachusetts General Hospital, Harvard Medical School, where he joined the faculty. In 2008, he moved to Boston University. His research focuses on Alzheimer’s disease, lens biology, traumatic brain injury, chronic traumatic encephalopathy, and laser-based diagnostic technologies.